Research Topics
| T Le ChevalierSummaryAffiliation: Institut Gustave Roussy Country: France Publications
| Collaborators
|
Detail Information
Publications
Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?T Le Chevalier
Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:vii196-8. 2010..If these results are confirmed, tailored therapy might be the next progress for resected NSCLC...
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesotheliomaK Fizazi
Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94800, Villejuif, France
Eur J Cancer 36:1514-21. 2000..The efficacy/toxicity ratio of this combination compares favourably with that of our previous chemotherapy and chemo-immunotherapy regimens...- Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implicationsF Andre
Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 18:2981-9. 2000..We analyzed the prognosis of patients with resected N2 NSCLC to propose homogeneous patient subgroups... - Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancerL Taillade
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 18:1043-50. 2007.... - Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancerC Monnerat
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
Ann Oncol 15:316-23. 2004..CONCLUSIONS: The results of the present study indicate that PKC412 at a dose of 50 mg/day can be safely added to cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer... - Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?J C Soria
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:1667-70. 2001..The objective of this study was to identify patients more likely to benefit from chemotherapy in order to avoid the indiscriminate treatment of all patients... - ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancerS Novello
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Lung Cancer 34:S107-9. 2001..On the basis of the results of the studies reviewed, it is clear that ALIMTA is emerging as a new drug in the management of NSCLC... - Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapyK Fizazi
Institut Gustave Roussy, Villejuif, France
J Clin Oncol 16:725-32. 1998..We describe the clinical and biologic features of these patients and evaluate the results of treatment during the cisplatin era... - Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective studyM Saghatchian
Institut Gustave Roussy, Villejuif, France
Ann Oncol 12:535-40. 2001..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site... - European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancerS Novello
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Semin Oncol 28:3-9. 2001..The use of paclitaxel in regimens without platinum and in triplet combinations is also being studied, and the optimal manner in which to administer this active agent clearly is of interest... - First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II studyA Llombart-Cussac
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Oncology 55:384-90. 1998..Mitoxantrone is an anthracenedione with low cardiotoxicity, and seems to be effective when combined with vinorelbine after prior exposure to anthracyclines... - Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokersT Dutu
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 16:1906-14. 2005..High levels of EGFR and Ki-67 are observed in smokers, while never-smokers are characterized by high levels of pAKT and p27... - Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?F Andre
Department of Medicine, Gustave Roussy Institute, Villejuif, France
Cancer 91:2394-400. 2001..The purpose of the current study was to analyze the patterns of relapse in these patients... - Is there a standard strategy in the management of locally advanced non-small cell lung cancer?S Novello
Departement of Medicine, Institut Gustave Roussy, Villejuif, France
Lung Cancer 34:S9-14. 2001..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity... - Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patientsR Arriagada
Institut Gustave Roussy, Villejuif, France
Ann Oncol 13:748-54. 2002..The current analysis aimed to evaluate PCI effects on patterns of failure in this patient category... - Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifenR Arriagada
Institut Gustave-Roussy, Villejuif, France
Ann Oncol 13:1378-86. 2002..Delaying radiotherapy after six courses of chemotherapy did not affect local control after up to 10 years of follow-up... - [Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation]C Le Pechoux
Departement de Radiotherapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
Rev Pneumol Clin 60:3S91-103. 2004.... - Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomesT Le Chevalier
Institute Gustave Roussy, 39 53 rue Camille Desmoulins, F 94800 Villejuif, France
Lung Cancer 47:69-80. 2005..This meta-analysis aims to quantify the treatment effect of gemcitabine plus a platinum agent in the treatment of advanced NSCLC and compare the combination to other regimens used globally... - Expanding role of chemotherapy in lung cancerY Loriot
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
Ann Oncol 17:x101-7. 2006 - Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?J C Soria
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 21:2324-32. 2010..In this article, we will evaluate the value of PFS as a primary measure of efficacy for advanced NSCLC, compare the clinical situation with that in other solid malignancies and review the growing number of treatment options for NSCLC... 
Ca125 and neuron-specific enolase (NSE) as tumour markers for intra-abdominal desmoplastic small round-cell tumoursK Fizazi
Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Br J Cancer 75:76-8. 1997..However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response...- Molecular prognostic factors in resectable non-small cell lung cancerP Vielh
Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Crit Rev Oncol Hematol 53:193-7. 2005..Of special interest are some molecular factors, already or currently tested from a prognostic point of view, that might also become good candidates for predicting treatment efficacy... - Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patientsF Griscelli
Department of Biology, Institut Gustave Roussy, Villejuif, France
Gene Ther 10:386-95. 2003..In addition, only on the day of the injection was Ad.RSVbetagal also detected in E1-positive PBL, indicating that virus replication in blood was very unlikely... - Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II studyK Fizazi
Department of Medicine, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 21:349-54. 2003..Most patients (66%) had advanced disease. Patients received raltitrexed 3 mg/m2 followed by oxaliplatin 130 mg/m2 every 3 weeks... - Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patientsA Auperin
Unit of Biostatistics and Epidemiology, Radiation Oncology and Medicine, Institut Gustave Roussy, Villejuif, France
Ann Oncol 17:473-83. 2006..Despite several randomised trials comparing radiotherapy alone with concomitant radio-chemotherapy in patients with locally advanced non-small cell lung cancer (NSCLC), it is not clear whether the addition of chemotherapy improves survival... - Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
Ann Oncol 13:1479-89. 2002..The RD was gemcitabine 1500 mg/m(2) and oxaliplatin 85 mg/m(2) every 2 weeks. Promising antitumor activity was reported in patients with NSCLC and platinum-pretreated OC, and thus, deserves further evaluation...